QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells

Mei Chuan Chen, Shiow Lin Pan, Qian Shi, Zhiyan Xiao, Kuo Hsiung Lee, Tsai Kun Li, Che Ming Teng

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Agents that cause DNA damage have been widely used as anticancer drugs because DNA lesions can initiate DNA checkpoints that induce cell death. The results presented here indicate that QS-ZYX-1-61, a derivative of VP-16, was significantly more potent than VP-16 in suppressing the viability of A549 cells. Treatment of cells with QS-ZYX-1-61 led to a DNA damage response and a dramatic increase of apoptosis. Our results also suggest that QS-ZYX-1-61 may be a topoisomerase (topo) II targeting agent, as evidenced by relaxation assay and induction of reversible cleavable complexes. Moreover, blocking of p53, topo IIα, and topo IIβ greatly protected against caspase-3 activation, poly-ADP-ribose polymerase cleavage, and cell growth inhibition, indicating that QS-ZYX-1-61 acts through these proteins. These results support our conclusion that QS-ZYX-1-61has potential as an anticancer agent because it causes accumulation of DNA cleavable complexes, with downstream consequences that include double-strand breaks and DNA damage response signaling for apoptosis. Taken together, our results indicate that QS-ZYX-1-61 is a novel DNA damaging agent and displays an outstanding activity that could be worthy of further investigation.

Original languageEnglish
Pages (from-to)80-87
Number of pages8
JournalCancer Science
Volume103
Issue number1
DOIs
Publication statusPublished - Jan 2012
Externally publishedYes

Fingerprint

Type II DNA Topoisomerase
Non-Small Cell Lung Carcinoma
Apoptosis
DNA Damage
DNA
Etoposide
Poly(ADP-ribose) Polymerases
Caspase 3
Antineoplastic Agents
Cell Death
A549 Cells
4-((4'-benzylpiperdin-4-yl)amino)-4'-O-demethylepipodophyllotoxin
Growth
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells. / Chen, Mei Chuan; Pan, Shiow Lin; Shi, Qian; Xiao, Zhiyan; Lee, Kuo Hsiung; Li, Tsai Kun; Teng, Che Ming.

In: Cancer Science, Vol. 103, No. 1, 01.2012, p. 80-87.

Research output: Contribution to journalArticle

Chen, Mei Chuan ; Pan, Shiow Lin ; Shi, Qian ; Xiao, Zhiyan ; Lee, Kuo Hsiung ; Li, Tsai Kun ; Teng, Che Ming. / QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells. In: Cancer Science. 2012 ; Vol. 103, No. 1. pp. 80-87.
@article{5fc4f4d7edc74eb89b28675e6b10556d,
title = "QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells",
abstract = "Agents that cause DNA damage have been widely used as anticancer drugs because DNA lesions can initiate DNA checkpoints that induce cell death. The results presented here indicate that QS-ZYX-1-61, a derivative of VP-16, was significantly more potent than VP-16 in suppressing the viability of A549 cells. Treatment of cells with QS-ZYX-1-61 led to a DNA damage response and a dramatic increase of apoptosis. Our results also suggest that QS-ZYX-1-61 may be a topoisomerase (topo) II targeting agent, as evidenced by relaxation assay and induction of reversible cleavable complexes. Moreover, blocking of p53, topo IIα, and topo IIβ greatly protected against caspase-3 activation, poly-ADP-ribose polymerase cleavage, and cell growth inhibition, indicating that QS-ZYX-1-61 acts through these proteins. These results support our conclusion that QS-ZYX-1-61has potential as an anticancer agent because it causes accumulation of DNA cleavable complexes, with downstream consequences that include double-strand breaks and DNA damage response signaling for apoptosis. Taken together, our results indicate that QS-ZYX-1-61 is a novel DNA damaging agent and displays an outstanding activity that could be worthy of further investigation.",
author = "Chen, {Mei Chuan} and Pan, {Shiow Lin} and Qian Shi and Zhiyan Xiao and Lee, {Kuo Hsiung} and Li, {Tsai Kun} and Teng, {Che Ming}",
year = "2012",
month = "1",
doi = "10.1111/j.1349-7006.2011.02103.x",
language = "English",
volume = "103",
pages = "80--87",
journal = "Cancer Science",
issn = "1347-9032",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - QS-ZYX-1-61 induces apoptosis through topoisomerase II in human non-small-cell lung cancer A549 cells

AU - Chen, Mei Chuan

AU - Pan, Shiow Lin

AU - Shi, Qian

AU - Xiao, Zhiyan

AU - Lee, Kuo Hsiung

AU - Li, Tsai Kun

AU - Teng, Che Ming

PY - 2012/1

Y1 - 2012/1

N2 - Agents that cause DNA damage have been widely used as anticancer drugs because DNA lesions can initiate DNA checkpoints that induce cell death. The results presented here indicate that QS-ZYX-1-61, a derivative of VP-16, was significantly more potent than VP-16 in suppressing the viability of A549 cells. Treatment of cells with QS-ZYX-1-61 led to a DNA damage response and a dramatic increase of apoptosis. Our results also suggest that QS-ZYX-1-61 may be a topoisomerase (topo) II targeting agent, as evidenced by relaxation assay and induction of reversible cleavable complexes. Moreover, blocking of p53, topo IIα, and topo IIβ greatly protected against caspase-3 activation, poly-ADP-ribose polymerase cleavage, and cell growth inhibition, indicating that QS-ZYX-1-61 acts through these proteins. These results support our conclusion that QS-ZYX-1-61has potential as an anticancer agent because it causes accumulation of DNA cleavable complexes, with downstream consequences that include double-strand breaks and DNA damage response signaling for apoptosis. Taken together, our results indicate that QS-ZYX-1-61 is a novel DNA damaging agent and displays an outstanding activity that could be worthy of further investigation.

AB - Agents that cause DNA damage have been widely used as anticancer drugs because DNA lesions can initiate DNA checkpoints that induce cell death. The results presented here indicate that QS-ZYX-1-61, a derivative of VP-16, was significantly more potent than VP-16 in suppressing the viability of A549 cells. Treatment of cells with QS-ZYX-1-61 led to a DNA damage response and a dramatic increase of apoptosis. Our results also suggest that QS-ZYX-1-61 may be a topoisomerase (topo) II targeting agent, as evidenced by relaxation assay and induction of reversible cleavable complexes. Moreover, blocking of p53, topo IIα, and topo IIβ greatly protected against caspase-3 activation, poly-ADP-ribose polymerase cleavage, and cell growth inhibition, indicating that QS-ZYX-1-61 acts through these proteins. These results support our conclusion that QS-ZYX-1-61has potential as an anticancer agent because it causes accumulation of DNA cleavable complexes, with downstream consequences that include double-strand breaks and DNA damage response signaling for apoptosis. Taken together, our results indicate that QS-ZYX-1-61 is a novel DNA damaging agent and displays an outstanding activity that could be worthy of further investigation.

UR - http://www.scopus.com/inward/record.url?scp=84855517944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84855517944&partnerID=8YFLogxK

U2 - 10.1111/j.1349-7006.2011.02103.x

DO - 10.1111/j.1349-7006.2011.02103.x

M3 - Article

C2 - 21920000

AN - SCOPUS:84855517944

VL - 103

SP - 80

EP - 87

JO - Cancer Science

JF - Cancer Science

SN - 1347-9032

IS - 1

ER -